The possible dual role of Ang-2 in the prognosis of pancreatic cancer.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
31 10 2023
Historique:
received: 15 05 2023
accepted: 17 10 2023
medline: 2 11 2023
pubmed: 1 11 2023
entrez: 1 11 2023
Statut: epublish

Résumé

Pancreatic ductal adenocarcinoma (PDAC) features a dense desmoplastic stroma, which raises the intratumoral interstitial pressure leading to vascular collapse and hypoxia, inducing angiogenesis. Vascular growth factors, such as vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2), increase in PDAC. A high VEGF and a high circulating Ang-2 associate with shorter survival in PDAC. In addition to the circulatory Ang-2, PDAC endothelial and epithelial cells express Ang-2. No correlation between tumor epithelial nor endothelial cell Ang-2 expression and survival has been published. We aimed to examine Ang-2 expression and survival. This study comprised PDAC surgical patients at Helsinki University Hospital in 2000-2013. Ang-2 immunohistochemistry staining was completed on 168 PDAC patient samples. Circulating Ang-2 levels were measured using ELISA in the sera of 196 patients. Ang-2 levels were assessed against clinical data and patient outcomes. A low tumor epithelial Ang-2 expression predicted shorter disease-specific survival (DSS) compared with a high expression (p = 0.003). A high serum Ang-2 associated with shorter DSS compared with a low circulating Ang-2 (p = 0.016). Ang-2 seemingly plays a dual role in PDAC survival. Further studies are needed to determine the mechanisms causing tumor cell Ang-2 expression and its positive association with survival.

Identifiants

pubmed: 37907568
doi: 10.1038/s41598-023-45194-0
pii: 10.1038/s41598-023-45194-0
pmc: PMC10618172
doi:

Substances chimiques

Angiopoietin-2 0
Vascular Endothelial Growth Factor A 0
Vascular Endothelial Growth Factors 0
ANGPT2 protein, human 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

18725

Informations de copyright

© 2023. The Author(s).

Références

J Clin Invest. 2012 Jun;122(6):1991-2005
pubmed: 22585576
Oncotarget. 2016 Sep 6;7(36):58649-58658
pubmed: 27462915
Am J Gastroenterol. 2017 Sep;112(9):1366-1372
pubmed: 28762376
Blood. 2010 Jul 29;116(4):584-92
pubmed: 20382847
Pancreas (Fairfax). 2019;3(1):e1-e4
pubmed: 32030361
PLoS One. 2016 Sep 15;11(9):e0163064
pubmed: 27632196
Mol Biotechnol. 2013 Mar;53(3):336-44
pubmed: 22457202
Blood. 2011 Nov 3;118(18):5050-9
pubmed: 21868579
Cancer Cell Int. 2016 Aug 25;16(1):65
pubmed: 27570490
J Pathol. 2008 Dec;216(4):387-93
pubmed: 18853439
Clin Cancer Res. 2018 Jun 15;24(12):2749-2757
pubmed: 29559563
Technol Cancer Res Treat. 2011 Aug;10(4):361-9
pubmed: 21728393
Cells. 2020 Feb 18;9(2):
pubmed: 32085414
Semin Oncol. 2016 Oct;43(5):548-553
pubmed: 27899186
Clin Genitourin Cancer. 2017 Feb;15(1):e15-e24
pubmed: 27554585
EMBO Mol Med. 2015 Dec 14;8(1):39-57
pubmed: 26666269
Clin Cancer Res. 2016 Mar 15;22(6):1348-55
pubmed: 26490310
Oncotarget. 2018 Jan 9;9(16):12705-12717
pubmed: 29560103
Cell Rep. 2017 Oct 31;21(5):1399-1410
pubmed: 29091775
Oncotarget. 2015 Jun 20;6(17):14940-52
pubmed: 25909285
J Natl Cancer Inst. 2012 Mar 21;104(6):461-75
pubmed: 22343031
J Am Coll Surg. 2004 Nov;199(5):724-31
pubmed: 15501112
Crit Care. 2008;12(4):R94
pubmed: 18664247
Cancer Cell. 2012 Mar 20;21(3):418-29
pubmed: 22439937
Nat Commun. 2015 Jan 30;6:5962
pubmed: 25635707
Proc Natl Acad Sci U S A. 2023 Jul 18;120(29):e2303740120
pubmed: 37428914
N Engl J Med. 1993 May 20;328(20):1433-7
pubmed: 8479461
Nat Rev Drug Discov. 2017 Sep;16(9):635-661
pubmed: 28529319
FASEB J. 2011 Oct;25(10):3325-35
pubmed: 21685330
Sci Transl Med. 2017 Apr 12;9(385):
pubmed: 28404865
Cancer Res. 2009 Feb 15;69(4):1324-33
pubmed: 19208839
PLoS One. 2011;6(5):e19773
pubmed: 21603628
Medicine (Baltimore). 2017 Sep;96(37):e8063
pubmed: 28906403
J Immunol. 2011 Apr 1;186(7):4183-90
pubmed: 21368233
Int J Cancer. 2020 Oct 1;147(7):2007-2018
pubmed: 32222972
Pancreatology. 2015 Jul-Aug;15(4):327-30
pubmed: 25975490

Auteurs

Matilda Roos-Mattila (M)

Department of Surgery, Helsinki University Hospital, Helsinki, Finland.
Translational Cancer Medicine Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
iCAN, Digital Cancer Precision Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.

Tuomas Kaprio (T)

Department of Surgery, Helsinki University Hospital, Helsinki, Finland. tuomas.kaprio@helsinki.fi.
Translational Cancer Medicine Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland. tuomas.kaprio@helsinki.fi.
iCAN, Digital Cancer Precision Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. tuomas.kaprio@helsinki.fi.
Department of Pathology, Haartmaninkatu 3 (PB 21), University of Helsinki, 00014, Helsinki, Finland. tuomas.kaprio@helsinki.fi.

Harri Mustonen (H)

Department of Surgery, Helsinki University Hospital, Helsinki, Finland.
Translational Cancer Medicine Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
iCAN, Digital Cancer Precision Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.

Jaana Hagström (J)

Department of Surgery, Helsinki University Hospital, Helsinki, Finland.
Translational Cancer Medicine Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
iCAN, Digital Cancer Precision Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Department of Oral Pathology and Radiology, University of Turku, Turku, Finland.

Pipsa Saharinen (P)

Wihuri Research Institute, Biomedicum Helsinki, University of Helsinki, Helsinki, Finland.
Translational Cancer Medicine Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
iCAN, Digital Cancer Precision Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.

Caj Haglund (C)

Department of Surgery, Helsinki University Hospital, Helsinki, Finland.
Translational Cancer Medicine Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
iCAN, Digital Cancer Precision Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.

Hanna Seppänen (H)

Department of Surgery, Helsinki University Hospital, Helsinki, Finland.
Translational Cancer Medicine Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
iCAN, Digital Cancer Precision Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH